Introduction: Understanding Humira (Adalimumab)
Humira (adalimumab) is a widely used biologic medication that helps manage several chronic inflammatory diseases, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis, and ankylosing spondylitis. It belongs to a class of drugs called TNF (tumor necrosis factor) inhibitors, which work by reducing inflammation in the body.
As one of the best-selling prescription drugs, Humira has transformed treatment options for autoimmune diseases. However, with the introduction of biosimilars, pricing strategies, PBM (pharmacy benefit manager) exclusions, and formulary changes in 2025, the cost and accessibility of Humira and its alternatives are rapidly evolving.
In this guide, we’ll cover:
- What Humira is used for
- How Humira works
- Dosage and administration
- Common and serious side effects
- How much Humira costs, biosimilar pricing strategies, and insurance coverage in 2025
What Is Humira Used For?
Humira is approved by the FDA for the treatment of multiple autoimmune diseases. It helps reduce pain, swelling, and inflammation by blocking TNF-alpha, a protein involved in immune system overactivity.
Conditions Treated by Humira:
- Rheumatoid Arthritis (RA) – Reduces joint inflammation and pain in adults with moderate to severe RA.
- Psoriatic Arthritis (PsA) – Helps prevent joint damage and improves skin symptoms.
- Ankylosing Spondylitis (AS) – Relieves spinal stiffness and inflammation.
- Crohn’s Disease – Controls bowel inflammation and prevents flare-ups.
- Ulcerative Colitis (UC) – Reduces inflammation and symptoms in moderate to severe cases.
- Plaque Psoriasis – Helps clear skin and reduce discomfort.
- Hidradenitis Suppurativa (HS) – Treats painful skin abscesses in moderate to severe cases.
- Uveitis – Treats inflammatory eye conditions to prevent vision loss.
- Juvenile Idiopathic Arthritis (JIA) – Approved for children with arthritis affecting multiple joints.
Regulatory Status of Humira (Adalimumab) in 2025
Humira is listed on the World Health Organization’s (WHO) List of Essential Medicines, highlighting its significance as a necessary treatment for chronic inflammatory diseases. This designation underscores the global medical importance of adalimumab despite ongoing cost and formulary challenges.
How Does Humira Work?
Humira is a monoclonal antibody that specifically targets tumor necrosis factor-alpha (TNF-α), a protein involved in inflammation. Overproduction of TNF-α leads to chronic inflammation, which is responsible for symptoms in autoimmune diseases.
By blocking TNF-α, Humira:
- Reduces swelling and pain in joints and tissues
- Prevents disease progression by lowering immune system overactivity
- Improves quality of life by decreasing flare-ups and symptoms
Humira Dosage and Administration
Humira is administered as a subcutaneous injection (under the skin) using either a pre-filled syringe or auto-injector pen. The dosage varies based on the condition being treated.
Standard Humira Dosage Guidelines
| Condition | Initial Dose | Maintenance Dose |
| Rheumatoid Arthritis | 40 mg every other week | 40 mg every other week |
| Psoriatic Arthritis | 40 mg every other week | 40 mg every other week |
| Ankylosing Spondylitis | 40 mg every other week | 40 mg every other week |
| Crohn’s Disease (Adults) | 160 mg (Week 0), 80 mg (Week 2) | 40 mg every other week |
| Ulcerative Colitis | 160 mg (Week 0), 80 mg (Week 2) | 40 mg every other week |
| Plaque Psoriasis | 80 mg (initial), then 40 mg every other week | 40 mg every other week |
| Hidradenitis Suppurativa | 160 mg (Week 0), 80 mg (Week 2) | 40 mg every week |
| Uveitis | 80 mg initial, then 40 mg every other week | 40 mg every other week |
Humira Cost, Pricing Strategies, and Insurance Coverage in 2025
As of Q4 2023, the net price per prescription for Humira ($2,798) was lower than for biosimilars, which ranged from $3,452 to $4,793. While biosimilars were initially expected to reduce costs, PBM pricing strategies and formulary exclusions have kept some biosimilar options more expensive than Humira in certain plans.
Pricing Strategies of Biosimilar Manufacturers & PBMs in 2025
Biosimilar manufacturers are employing two pricing strategies:
- High-list-price, high-rebate model – Helps PBMs secure larger rebates but keeps net prices high.
- Low-list-price, transparent pricing model – Designed to lower out-of-pocket costs but may not be favored by PBMs.
Interchangeability and Biosimilar Market in 2025
Some adalimumab biosimilars are now FDA-approved as interchangeable, meaning they can be substituted for Humira without prescriber intervention. However, due to PBM formulary exclusions, many patients may not have access to them.
PBM Strategies and Formulary Exclusions
- Most marketed biosimilars are excluded from major PBM formularies in 2025, limiting patient access.
- PBMs are prioritizing private-label versions of adalimumab instead of third-party biosimilars.
- Optum Rx’s 2025 formulary changes have altered coverage for multiple adalimumab products, affecting patient affordability.
Frequently Asked Questions About Humira
1. How long does Humira take to work?
Most patients start seeing improvement within 2 to 12 weeks, depending on the condition being treated.
2. Can I stop taking Humira suddenly?
Stopping Humira without a doctor’s guidance can cause disease flare-ups. Always consult your healthcare provider before discontinuing treatment.
3. Is Humira a steroid?
No, Humira is a biologic medication, not a steroid. It targets TNF-α to reduce inflammation.
4. Can I take Humira if I have an infection?
No, Humira weakens the immune system, so it should not be taken if you have an active infection.
5. Are there alternatives to Humira?
Yes, biosimilars like Amjevita, Cyltezo, and Hadlima offer lower-cost options, though formulary exclusions limit access in some insurance plans.
Final Thoughts: Is Humira Right for You?
Humira (adalimumab) is a highly effective biologic for managing chronic autoimmune conditions. However, with biosimilar pricing complexities, PBM formulary exclusions, and interchangeability status evolving in 2025, patients should work closely with their doctor and insurer to determine the best and most cost-effective treatment option.
If you’re considering Humira, speak to your healthcare provider about risks, benefits, and financial assistance programs that may help with affordability.
